Other equities research analysts also recently issued reports about the company. Stifel Nicolaus reissued a buy rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, September 1st. Piper Jaffray Companies set a $73.00 target price on Zoetis and gave the stock a buy rating in a research report on Friday, August 25th. Cowen set a $70.00 target price on Zoetis and gave the stock a buy rating in a research report on Thursday, August 24th. BidaskClub lowered Zoetis from a strong-buy rating to a buy rating in a research report on Wednesday, September 20th. Finally, Zacks Investment Research raised Zoetis from a hold rating to a buy rating and set a $71.00 target price on the stock in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $68.53.
Shares of Zoetis (ZTS) opened at $71.76 on Tuesday. The stock has a market capitalization of $35,269.93, a PE ratio of 33.20, a P/E/G ratio of 2.17 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a one year low of $51.66 and a one year high of $72.99.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be issued a dividend of $0.126 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.70%. Zoetis’s dividend payout ratio is currently 22.11%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wilbanks Smith & Thomas Asset Management LLC grew its holdings in Zoetis by 1.8% in the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock valued at $354,000 after buying an additional 98 shares during the last quarter. Scotia Capital Inc. grew its holdings in Zoetis by 1.5% in the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock valued at $601,000 after buying an additional 142 shares during the last quarter. Nordea Investment Management AB grew its holdings in Zoetis by 0.7% in the 2nd quarter. Nordea Investment Management AB now owns 24,854 shares of the company’s stock valued at $1,550,000 after buying an additional 169 shares during the last quarter. Moors & Cabot Inc. grew its holdings in Zoetis by 1.1% in the 2nd quarter. Moors & Cabot Inc. now owns 14,969 shares of the company’s stock valued at $929,000 after buying an additional 170 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its holdings in Zoetis by 8.5% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 2,789 shares of the company’s stock valued at $174,000 after buying an additional 219 shares during the last quarter. 93.33% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/15/cantor-fitzgerald-reiterates-80-00-price-target-for-zoetis-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.